BioSpace News Archive

Cutera, Inc., a leading provider of aesthetic and dermatology solutions, reported financial results for the fourth quarter and full-year ended December 31, 2022.

Amarin Corporation plc announced that, based on the preliminary voting results provided by its proxy solicitors following the Company’s 2023 General Meeting of Shareholders, Amarin shareholders have voted to elect all seven of Sarissa’s nominees and remove Per Wold-Olsen as Chairman of the Board of Directors, effective immediately.

Together with FloSpine, LLC, the Research Park at Florida Atlantic University® is pleased to announce that FloSpine has achieved 510(k) clearance for its first 3D Printed Titanium Ti-Largo™ Cervical Interbody Cage System from the Food and Drug Administration (FDA).

G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology company, today announced that on March 7th, 2023, at 10:30 AM EST, G1’s Chief Executive Officer Jack Bailey will participate in the moderated Breast and Lung Cancer Panel during the Cowen 43rd Annual Health Care Conference.

Kronos Bio, Inc. announced participation in the 43rd Annual Cowen Health Care Conference, taking place March 6-8, 2023, in Boston, Massachusetts.

Regulatory News: Median Technologies announces new and breakthrough results for its iBiopsy® Lung Cancer Screening AI/ML tech-based CADe/CADx1 Software as Medical Device to characterize malignant lung nodules in low dose CT scans.

Pixium Vision SA informs its shareholders that the Extraordinary Shareholder Meeting of the Company, convened a second call to vote on the same agenda and draft resolutions as the extraordinary shareholder meeting of February 15, 2023, will be held on Wednesday March 8, 2023 at 10:30 am CET at the headquarter of Pixium Vision, 74 rue du faubourg Saint Antoine in Paris.

Centinel Spine®, LLC, (“the Company”) today announced that Steven Murray, Chief Executive Officer, and Varun Gandhi, Chief Financial Officer, will participate in the Canaccord Genuity 2023 Musculoskeletal Conference on Tuesday, March 7, 2023.

The U.S. Food and Drug Administration announced that it has begun a national search for a new Deputy Commissioner for Human Foods and is providing an update on last month’s proposed restructuring of the agency’s Human Foods Program and Office of Regulatory Affairs to enhance coordination, prevention and response activities.

Fulgent Genetics, Inc. (NASDAQ: FLGT) (“Fulgent”, or the “Company”), a technology-based company with a well-established clinical diagnostic business and a therapeutic development business, today announced financial results for its fourth quarter and full year ended December 31, 2022.